Laboratory Corp. of America Holdings (LH) : National Investment Services Inc Wi scooped up 7,811 additional shares in Laboratory Corp. of America Holdings during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 18, 2016. The investment management firm now holds a total of 23,872 shares of Laboratory Corp. of America Holdings which is valued at $2,906,893.Laboratory Corp. of America Holdings makes up approximately 3.25% of National Investment Services Inc Wi’s portfolio.
Laboratory Corp. of America Holdings opened for trading at $121.21 and hit $122.02 on the upside on Friday, eventually ending the session at $121.77, with a gain of 0.64% or 0.77 points. The heightened volatility saw the trading volume jump to 15,43,310 shares. Company has a market cap of $12,384 M.
Other Hedge Funds, Including , Gateway Investment Advisers reduced its stake in LH by selling 3,298 shares or 30.68% in the most recent quarter. The Hedge Fund company now holds 7,452 shares of LH which is valued at $907,430. Laboratory Corp. of America Holdings makes up approx 0.01% of Gateway Investment Advisers’s portfolio.Endurance Wealth Management reduced its stake in LH by selling 25 shares or 1.56% in the most recent quarter. The Hedge Fund company now holds 1,575 shares of LH which is valued at $188,307. Laboratory Corp. of America Holdings makes up approx 0.04% of Endurance Wealth Management’s portfolio.Contravisory Investment Management reduced its stake in LH by selling 3,137 shares or 4.84% in the most recent quarter. The Hedge Fund company now holds 61,664 shares of LH which is valued at $7,372,548. Laboratory Corp. of America Holdings makes up approx 2.15% of Contravisory Investment Management’s portfolio. Lenox Wealth Advisors sold out all of its stake in LH during the most recent quarter. The investment firm sold 26 shares of LH which is valued $3,109.
On the company’s financial health, Laboratory Corp. of America Holdings reported $1.98 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Feb 18, 2016. Analyst had a consensus of $2.00. The company had revenue of $2244.80 million for the quarter, compared to analysts expectations of $2220.77 million. The company’s revenue was up 48.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.65 EPS.
Many Wall Street Analysts have commented on Laboratory Corp. of America Holdings. Laboratory Corp. of America Holdings was Initiated by Credit Suisse to “Outperform” on Mar 16, 2016. Shares were Reiterated by RBC Capital Mkts on Feb 19, 2016 to “Sector Perform” and Lowered the Price Target to $ 130 from a previous price target of $135 .
Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing patient diagnosis and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment which includes core testing as well as genomic and esoteric testing; and the Other segment which consists of the Company’s non-United States clinical diagnostic laboratory operations in Ontario Canada. It also provides specialty testing services in the areas of allergy clinical trials diagnostic genetics women’s health cardiovascular disease identity forensics infectious disease endocrinology oncology coagulation occupational testing and pain management.